Factors Influencing the Emergence and Spread of HIV Drug Resistance Arising from Rollout of Antiretroviral Pre-Exposure Prophylaxis (PrEP) by Abbas, Ume L. et al.
Factors Influencing the Emergence and Spread of HIV
Drug Resistance Arising from Rollout of Antiretroviral
Pre-Exposure Prophylaxis (PrEP)
Ume L. Abbas
1*, Gregory Hood
2, Arthur W. Wetzel
2, John W. Mellors
3
1Department of Infectious Diseases, Cleveland Clinic Foundation, Cleveland, Ohio, United States of America, 2Pittsburgh Supercomputing Center, Pittsburgh,
Pennsylvania, United States of America, 3Division of Infectious Diseases, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
Abstract
Background: The potential for emergence and spread of HIV drug resistance from rollout of antiretroviral (ARV) pre-
exposure prophylaxis (PrEP) is an important public health concern. We investigated determinants of HIV drug resistance
prevalence after PrEP implementation through mathematical modeling.
Methodology: A model incorporating heterogeneity in age, gender, sexual activity, HIV infection status, stage of disease,
PrEP coverage/discontinuation, and HIV drug susceptibility, was designed to simulate the impact of PrEP on HIV prevention
and drug resistance in a sub-Saharan epidemic.
Principal Findings: Analyses suggest that the prevalence of HIV drug resistance is influenced most by the extent and
duration of inadvertent PrEP use in individuals already infected with HIV. Other key factors affecting drug resistance
prevalence include the persistence time of transmitted resistance and the duration of inadvertent PrEP use in individuals
who become infected on PrEP. From uncertainty analysis, the median overall prevalence of drug resistance at 10 years was
predicted to be 9.2% (interquartile range 6.9%–12.2%). An optimistic scenario of 75% PrEP efficacy, 60% coverage of the
susceptible population, and 5% inadvertent PrEP use predicts a rise in HIV drug resistance prevalence to only 2.5% after 10
years. By contrast, in a pessimistic scenario of 25% PrEP efficacy, 15% population coverage, and 25% inadvertent PrEP use,
resistance prevalence increased to over 40%.
Conclusions: Inadvertent PrEP use in previously-infected individuals is the major determinant of HIV drug resistance
prevalence arising from PrEP. Both the rate and duration of inadvertent PrEP use are key factors. PrEP rollout programs
should include routine monitoring of HIV infection status to limit the spread of drug resistance.
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Introduction
Antiretroviral (ARV) pre-exposure prophylaxis (PrEP) is a
promising HIV prevention strategy [1,2]. There is widespread
concern, however, about the potential emergence and spread of
HIV drug resistance arising from PrEP rollout, particularly in
resource-constrained settings, where antiretroviral treatment
options are limited. This concern is amplified by the possibility
that the same antiretroviral drugs will be used for both treatment
and PrEP. Insight is needed into factors influencing the emergence
and spread of HIV drug resistance at the population level from
PrEP [3]. We therefore used a mathematical model to analyze the
potential impact of orally administered PrEP on HIV drug
resistance outcomes through simulation of different PrEP
implementation scenarios. The focus of the current work was to
identify major determinants of HIV drug resistance prevalence
after PrEP implementation rather than prediction of actual
outcomes.
Methods
Model Structure
We have developed and analyzed a population model of
heterosexual HIV transmission and disease progression to assess
the impact of PrEP implementation [4]. In brief, the model
consists of coupled, nonlinear differential equations describing
population and epidemiological stratifications based on gender,
age, sexual activity, PrEP use status (on/off), infection status
(susceptible/infected), stage of HIV infection, and HIV drug
susceptibility. Model input parameters were chosen to simulate a
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18165mature epidemic in southern sub-Saharan Africa [4]. Parameter
assignments were made from recent literature on HIV disease
progression, infectivity, sexual behavior and the emergence,
transmission and persistence of HIV drug resistance.
For the present work, we extended our published model [4] by
incorporating detailed representation of HIV drug resistance, both
transmitted and acquired, arising from PrEP as outlined in
Figure 1, and with parameter assignments listed in Table 1. Model
equations and details are provided in Appendix S1. In addition to
PrEP use in susceptible individuals, we model inadvertent PrEP
use in individuals previously HIV-infected (pre-infected) as well as
those who become infected while on PrEP (post-infected). The
final model describes a sexually active population (15–49 year-
olds) that is stratified into many different states based on
epidemiologic, demographic and behavioral characteristics, in-
cluding 22 unique HIV drug susceptibility strata described below.
Effectiveness of PrEP. Our model represents the
transmission of HIV as a Poisson process [3]. The probability of
transmission per heterosexual partnership, b, between an
individual (on PrEP) of gender g, activity level k, and age i, with
an (infected) individual of opposite gender g9, activity level l and
age j is given by:
b
VH
g’lj ~1{ 1{cVH
g’lj 1{jh ðÞ
no Ygg’klij
where Y is the number of sex acts within the partnership; c is the
probability of HIV transmission per sex-act (infectivity) based on
the disease stage, V, and drug resistance status, H, of the infected
partner; and jh is the effectiveness of PrEP. Effectiveness is defined
as the probability of preventing HIV transmission per sex-act
through PrEP and is given by the product of the average efficacy
of PrEP, j (the degree of protection provided, from HIV
transmission per sex-act) and the average level of adherence to
PrEP, h (assuming once daily dosing of a single antiretroviral drug
and that doses are missed at random). In a partnership, where the
infected partner harbors major drug-resistant variants (discussed
below), the probability of transmission of resistant virus is ub, while
that of wild-type virus is (12u)b, and the effectiveness of PrEP
against resistant virus is ijh. The parameters j, h, u and i assume
values between 0 and 1 (Table 1).
Modeling Drug Resistance. We sub-classified HIV-infected
individuals based on their PrEP status (naı ¨ve, on PrEP or off
PrEP), HIV drug susceptibility (drug-sensitive or drug-resistant),
type of drug resistance (transmitted or acquired), and virus
population dynamics of drug-resistant HIV (persistence of
resistance or reversion of resistance, the latter either from
genetic reversion of virus to wild-type or overgrowth of resistant
virus by wild-type virus) into 22 different HIV drug susceptibility
strata (Figure 1 and Tables 1, 2). Our key model assumptions for
HIV drug resistance are as follows. In an HIV-infected individual,
the virus population is comprised of a set of related variants,
termed a quasispecies [5]. Before the introduction of PrEP in
antiretroviral naı ¨ve persons, the major (predominant) variants are
wild-type and drug-sensitive. After the introduction of PrEP, drug-
sensitive virus or drug-resistant variants may predominate.
Individuals with predominantly drug-sensitive or drug-resistant
variants may probabilistically transmit either drug-sensitive or
drug-resistant virus to their sexual partners (Table 1). Transmitted
resistance (Table 2) may occur from: i) a donor having a majority
Figure 1. Simplified Model Flow Diagram. A. Resistant=acquired resistance and T. Resistance=transmitted resistance.
doi:10.1371/journal.pone.0018165.g001
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or not receiving PrEP; or ii) a donor having a majority population
of drug-sensitive virus to a recipient receiving PrEP. Acquired
resistance may occur from the selection of drug-resistant virus in
individuals with drug-sensitive virus, who were either previously
infected or became infected while receiving PrEP [5,6]. Upon
removal of drug selection, either by discontinuation of PrEP [7] or
transmission to an individual not on PrEP (never started or
discontinued) [8], the drug-resistant virus reverts to drug-sensitive
virus after a period of persistence, either from overgrowth of
resistant variants by wild-type variants or genetic reversion of the
resistant variants to wild-type [9,10,11]. Prior to reversion, drug-
resistant variants comprise the majority population, whereas
following reversion they become a minor population [6,12,13].
Compared to individuals with wild-type virus, individuals with
majority resistant variants may have: i) decreased per act
probability of transmission of HIV to their sexual partners
(infectivity) because of reduced transmission fitness or from lower
virus levels, the latter either from continued antiretroviral activity
of PrEP [7,14] or from reduced viral replicative fitness [9,15,16];
and ii) increased probability of sexual transmission of drug-
resistant strains versus drug-sensitive strains [17,18,19].
Table 1. Model Parameters for PrEP Scenarios.
PARAMETER UNIT SENSITIVITY SCENARIO REFERENCE
LHS{ RANGE OPTIMISTIC REALISTIC PESSIMISTIC
Fraction of individuals enrolled into PrEP (coverage) per year 0.15–0.60 0.60 0.30 0.15 Assumption
Time period to achieve target coverage year 1–10 1 5 10 Assumption
Efficacy of PrEP against sensitive virus (j) - 0.25–0.75 0.75 0.50 0.25 Assumption
(Relative) Efficacy of PrEP against resistant virus (j
R=i*j) - 0.00–0.25 * j 0.25* j 0.125* j 0* j Assumption
Adherence (h) - 0.25–0.75 0.75 0.50 0.25 Assumption
PrEP discontinuation rate in susceptible individuals per year 0.05–0.25 0.05 0.10 0.25 Assumption
Duration of inadvertent PrEP use in those who become
infected on PrEP
year 0.5–3 0.5 1 3 Assumption
Rate of inadvertent PrEP uptake in previously-infected
individuals
per year 0.05–0.25 0.05 0.10 0.25 Assumption
Duration of inadvertent PrEP use in previously-infected
individuals
year 0.5–3 0.5 1 3 Assumption
Time to development of acquired resistance in inadvertent
PrEP users who become infected on PrEP (t1)
year 0.167–0.5 0.5 0.25 0.167 [5]
Rate of development of acquired resistance in inadvertent
PrEP users who become infected on PrEP
per year derived 2LN(120.99*h)/t1 2LN(120.99*h)/t1 2LN(120.99*h)/t1 [46]
Time to development of acquired resistance in inadvertent
PrEP users who are previously infected (t2)
year 0.083–0.25 0.25 0.125 0.083 [38,39]
Rate of development of acquired resistance in inadvertent
PrEP users who are previously infected
per year derived 2LN(120.99*h)/t2 2LN(120.99*h)/t2 2LN(120.99*h)/t2 [46]
Infectivity of donor with transmitted resistance* per act 0.5–1.0 * c
V 0.5 0.75 1 [7,9,14,15,16]
Infectivity of donor with acquired resistance* per act 0.5–1.0 * c
V 0.5 0.75 1 [7,9,14]
Probability of transmission of resistant versus sensitive
virus from donor with transmitted resistance
- 0.75–1.0 0.75 0.9 1 [17,18,19]
Probability of transmission of resistant versus sensitive
virus from a donor with acquired resistance
- 0.5–1.0 0.5 0.75 1 [17,18,19]
Probability of transmission of resistant versus sensitive
virus from a donor with wild-type or reverted to
wild-type virus to a recipient on PrEP
- 0.01–0.25 0.01 0.05 0.25 Assumption
Persistence time of transmitted resistance in recipients
not on PrEP
year 1–5 1 2 5 [8,10,22]
Persistence time of transmitted resistance in recipients
after PrEP discontinuation
year 1–5 1 2 5 [8,10,22]
Persistence time of acquired resistance after PrEP
discontinuation
year 0.083–1 0.083 0.5 1 [7,9,11]
Factor increase in rates of sexual partnership change
of individuals, both susceptible and infected, while
on PrEP (i.e., risk compensation)
- 1.0–2.0 1.0–2.0 1.0–2.0 1.0–2.0 Assumption
HIV disease progression [4] was assumed the same for drug-resistant and drug-sensitive virus because: i) a temporary predominance of drug-resistant mutants was
assumed in the model; and ii) though lower viremia has been observed in the experimental setting [14], it is unknown whether PrEP would attenuate the course of HIV
infection.
HIV infectivity and disease progression [4] in individuals with drug-sensitive virus were assumed to be unchanged by their PrEP status.
*Relative to infectivity (per sex act probability of transmission) of donor with wild-type virus based on stage of infection, c
V [4].
{Latin Hypercube Sampling (uniform distribution).
doi:10.1371/journal.pone.0018165.t001
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individuals with majority wild-type variants in terms of HIV
transmission and disease progression. The re-emergence of drug-
resistant variants from antiretroviral therapy was not modeled
[20,21,22].
Model Output and Introduction of PrEP. The model’s
dynamical behavior was investigated using numerical methods.
The key model outputs were: i) HIV incidence; ii) HIV prevalence;
iii) cumulative new HIV infections; iv) proportion of cumulative
new infections with transmitted resistance; v) overall prevalence of
HIV drug resistance (transmitted plus acquired); vi) prevalence of
transmitted resistance; and vii) prevalence of acquired resistance.
PrEP was introduced (once daily oral dosing of a single
antiretroviral drug, e.g. tenofovir disoproxil fumarate) at
endemic equilibrium when HIV prevalence in sexually active
adults (15–49 year-olds) was approximately 20%. We made
comparisons between the epidemics with and without PrEP at
each simulation time-step over a 10 year interval after PrEP
introduction.
Sensitivity Analyses
We performed sensitivity analyses [23,24] to determine the
relative influence of PrEP-related input parameters (Table 1) on
outcomes and examined our prediction uncertainty [25]. Univar-
iate sensitivity analyses were performed using batch simulations in
which the PrEP-related input parameters were individually varied,
over their entire range, followed by examination of tornado and
contour plots of output. For multivariate time-dependent sensitiv-
ity analyses, we performed two sets of 10,000 runs using Latin
hypercube sampling to simulate HIV epidemics and the
implementation of PrEP, either with or without risk compensation
(increase in rate of sex partner change) occurring in the population
on PrEP. We rank transformed input and output data obtained
from simulations and derived standardized rank regression
coefficients (SRRCs) [26]. The strength and nature of the
relationship between an input parameter and the outcome are
given by the size and sign (+/2) of the relevant SRRC. Because
we sampled the input parameters independently, the fraction of
variance in model outcome explained by each parameter is given
by the square of its SRRC [27,28]. In addition to the model’s
sensitivity to parameter uncertainty, we studied the model’s
sensitivity to key assumptions by comparing the outputs of an
original model with those obtained using different structural
assumptions (singly or combined) including no PrEP use in
previously-infected individuals.
PrEP Scenarios
The impact of PrEP was next determined by simulating three
different scenarios: optimistic, realistic and pessimistic (Table 1).
For each of these scenarios, we simulated PrEP implementation
with proportional PrEP coverage in the following susceptible
populations: i) the sexually active population in general (non-
targeted strategy); ii) targeted to the group 15–20 years of age
(targeted-by-age strategy); iii) targeted to the female population
(targeted-by-gender strategy); and iv) targeted to the two highest
sexual activity levels (targeted-by-activity strategy). In addition, the
scenarios (optimistic, realistic and pessimistic) represented inad-
vertent PrEP use in the previously-infected population (rates/year
of 5%, 10% and 25%) as well as in all the individuals infected on
PrEP, for a variable period of time.
Results
Our mathematical model stratifies the study population by
gender, age, sexual activity level, PrEP use, HIV infection status,
disease stage and HIV drug susceptibility (Figure 1), and its
dynamical behavior is analyzed numerically. We introduced PrEP
at endemic equilibrium and simulated optimistic, realistic and
pessimistic scenarios (Table 1). For each scenario we simulated
four strategies of PrEP implementation: i) in the sexually active
population in general (non-targeted strategy); ii) targeted to the
group 15–20 years of age (targeted-by-age strategy); iii) targeted to
the female population (targeted-by-gender strategy); and iv)
targeted to the two highest sexual activity levels (targeted-by-
activity strategy). To determine the epidemiological impact of
PrEP, we compared epidemics with and without PrEP for up to 10
years for: i) HIV incidence; ii) HIV prevalence; iii) cumulative new
HIV infections; in addition we determined outcomes of drug
resistance from PrEP including iv) proportion of cumulative new
infections with transmitted resistance; v) overall prevalence of HIV
drug resistance (transmitted plus acquired); vi) prevalence of
transmitted resistance; and vii) prevalence of acquired resistance.
Factors Influencing Impact of PrEP on Transmission vs.
HIV Drug Resistance
Table 3 shows multivariate sensitivity analyses of model
outcomes after 10 years of PrEP implementation in the absence
of risk compensation. The key parameters influencing the impact
of PrEP on HIV prevention were different from those affecting the
Table 2. Model Cases for HIV Transmission.
HIV Donor HIV Recipient
Case
PrEP
Status Majority Variant
PrEP
Status
Transmitted
Variant
1 2 Wild-type 2 Sensitive
2 + Wild-type 2 Sensitive
3 2 Wild-type + Sensitive
4 2 Wild-type + Resistant
5 + Wild-type + Sensitive
6 + Wild-type + Resistant
7 2 Acquired Resistant 2 Sensitive
8 2 Acquired Resistant 2 Resistant
9 2 Acquired Resistant + Sensitive
10 2 Acquired Resistant + Resistant
11 + Acquired Resistant 2 Sensitive
12 + Acquired Resistant 2 Resistant
13 + Acquired Resistant + Sensitive
14 + Acquired Resistant + Resistant
15 2 Transmitted Resistant 2 Sensitive
16 2 Transmitted Resistant 2 Resistant
17 2 Transmitted Resistant + Sensitive
18 2 Transmitted Resistant + Resistant
19 + Transmitted Resistant 2 Sensitive
20 + Transmitted Resistant 2 Resistant
21 + Transmitted Resistant + Sensitive
22 + Transmitted Resistant + Resistant
23 2 Reverted to Wild-type 2 Sensitive
24 2 Reverted to Wild-type + Sensitive
25 2 Reverted to Wild-type + Resistant
doi:10.1371/journal.pone.0018165.t002
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coverage (SRRC=0.52) explained 26.9% of the variance in
cumulative infections prevented. The level of PrEP adherence
(SRRC=0.49), PrEP efficacy against wild-type virus (SRRC=
0.42), infectivity of individuals with acquired resistance (SRRC=
20.32), and the rate of PrEP discontinuation in susceptible
individuals (SRRC=20.23) explained 24%, 17.5%, 9.9% and
5.4% of the variance in infections prevented, respectively.
By contrast, the overall prevalence of drug resistance was
influenced most by the duration of inadvertent PrEP use
(SRRC=0.62) and the rate of PrEP uptake (SRRC=0.34) in
previously-infected individuals. Together these two parameters
explained 50.5% of the variance in overall prevalence of resistance
after 10 years. Not surprisingly, the prevalence of transmitted
resistance after 10 years was most influenced by the persistence
time of transmitted resistance (SRRC=0.53), explaining 28% of
the variance. The rate of PrEP uptake and duration of inadvertent
use in previously-infected individuals (SRRC=0.32) explained
another 10.5% and 10.2% of variance in transmitted resistance,
respectively. The prevalence of acquired resistance was most
sensitive to the duration of inadvertent PrEP use (SRRC=0.74)
and its rate of uptake (SRRC=0.27) in previously-infected
individuals; together these parameters explained 61.6% of the
variance in the prevalence of acquired resistance after 10 years.
Likewise, the rate (SRRC=0.40) and duration (SRRC=0.36) of
inadvertent PrEP use in previously-infected individuals were most
influential for the proportion of cumulative new infections with
transmitted resistance, explaining 28.8% of the variance in this
outcome (data not shown). Factors influencing the prevalence of
drug resistance when risk compensation was assumed were similar
to the above (data not shown).
Scenario Analysis
Table 1 shows the PrEP-related input parameters for the three
different scenarios. Table 4 compares the epidemiologic outcomes
in optimistic, realistic and pessimistic scenarios 10 years after the
Table 3. Sensitivity Analysis of Outcomes after 10 years of PrEP Implementation.
Model Input* Model Output
Cumulative New
Infections
Prevented
Prevalence of
Overall
Resistance{
Prevalence of
Transmitted
Resistance{
Prevalence of
Acquired
Resistance{
Standardized Rank Regression Coefficients (% variance explained1)
PrEP Coverage 0.52 (26.9)
Adherence 0.49 (24.0)
Efficacy of PrEP against sensitive virus 0.42 (17.5)
Infectivity of individuals with acquired resistance 20.32 (9.9)
PrEP discontinuation rate in susceptible individuals 20.23 (5.4)
Duration of inadvertent PrEP use in pre-infected individuals 0.62 (38.8) 0.32 (10.2) 0.74 (54.1)
Rate of inadvertent PrEP uptake in pre-infected individuals 0.34 (11.7) 0.32 (10.5) 0.27 (7.5)
Duration of inadvertent PrEP use in post-infected individuals 0.30 (9.2) 0.32 (10.0)
Persistence time of transmitted resistance 0.28 (7.6) 0.53 (28.0)
Persistence time of acquired resistance 0.25 (6.0)
*Parameters that contribute 5% or more of the variance in the model outcome are shown (SRRC
2$0.05). The reported coefficients were significant with a p-value#0.05.
1Of the total variance in the predicted outcome explained by the regression model. The respective R
2 values were: 0.91 (cumulative infections prevented); 0.85 (overall
prevalence of resistance); 0.89 (prevalence of transmitted resistance); 0.85 (prevalence of acquired resistance); and 0.89 (resistant cumulative infections).
{Proportion of cases with drug-resistant infection in the infected population.
doi:10.1371/journal.pone.0018165.t003
Table 4. Outcomes for Optimistic (O), Realistic (R) and Pessimistic (P) Scenarios after 10 Years of PrEP Implementation.
Non-Targeted Targeted-by-Age Targeted-by-Gender Targeted-by-Activity
ORPORPORPORP
Overall prevalence* of resistance 2.5% 9.9% 42.3% 2.4% 9.7% 42.4% 2.1% 9.3% 42.3% 1.9% 9.2% 42.5%
Prevalence* of transmitted resistance 0.4% 2.9% 27.1% 0.3% 2.7% 27.0% 0.2% 2.5% 26.9% 0.2% 2.5% 26.9%
Prevalence* of acquired resistance 2.2% 7.0% 15.2% 2.1% 7.0% 15.4% 1.9% 6.8% 15.5% 1.7% 6.6% 15.6%
Cumulative new infections prevented 30.3% 6.6% 0.2% 17.5% 4.5% 0.1% 18.5% 4.6% 0.1% 8.0% 3.0% 0.0%
Resistant cumulative infections{ 2.2% 8.3% 40.3% 1.5% 7.4% 39.9% 1.3% 7.0% 39.7% 1.3% 7.1% 39.7%
Decline in HIV prevalence 26.2% 6.0% 0.2% 16.6% 4.2% 0.1% 16.2% 4.2% 0.1% 7.1% 2.7% 0.0%
Decline in HIV incidence 32.3% 7.4% 0.2% 25.4% 6.0% 0.1% 20.2% 5.3% 0.1% 8.6% 3.2% 0.0%
*Proportion of cases with drug-resistant infection in the infected population.
{Proportion of cumulative new infections with transmitted resistance.
doi:10.1371/journal.pone.0018165.t004
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was highest for the pessimistic scenario (42.3%), but was minimal
for the optimistic scenario (2.5%), illustrating the importance of
the key scenario parameters on resistance prevalence (Figure 2A).
With uncertainty analysis (Figure 3), the median overall prevalence
of drug resistance at 10 years was 9.2% (interquartile range 6.9%–
12.2%), similar to the resistance prevalence for the realistic
scenario (9.9%). For both the optimistic and the realistic scenario,
the non-targeted strategy generated the most resistance, whereas
the targeted-by-activity strategy generally produced the least
resistance with the following rank order of resistance prevalence:
non-targeted.targeted-by-age.targeted-by-gender.targeted-by-
activity. By contrast, high resistance prevalence was seen with the
pessimistic scenario across the four different strategies (Table 4 and
Figure 2A).
For each scenario, the largest decrease in infections was
achieved with the non-targeted strategy and the smallest decrease
with the targeted-by-activity strategy (Table 4 and Figure 2B).
Specifically, a 30.3% reduction in infections occurred for the
optimistic scenario, 6.6% for the realistic scenario and 0.2% for
the pessimistic scenario with the non-targeted strategy. These
reductions fell to 8%, 3% and 0%, respectively, with the targeted-
by-activity strategy. However, the proportion of cumulative
infections with transmitted resistance also fell with the targeted-
by-activity strategy: from 2.2% to 1.3% for the optimistic scenario:
from 8.3% to 7.1% for the realistic scenario; and minimally from
40.3% to 39.7% for the pessimistic scenario. The targeted-by age
and targeted by-gender strategies yielded intermediate declines in
infections (17.5%, 4.5%, 0.1% and 18.5%, 4.6%, 0.1%,
respectively). Overall, the declines in HIV prevalence and
incidence were highest for the optimistic scenario (26.2% and
32.3%, respectively, for the non-targeted strategy) with minimal
changes observed with the pessimistic scenario (0.2% for the non-
targeted strategy).
Univariate sensitivity analyses of resistance prevalence con-
firmed that the most important factors affecting resistance
prevalence were the rate and duration of use of inadvertent PrEP
in previously-infected individuals. When no inadvertent PrEP use
in previously infected individuals was assumed, there was a major
decline in the prevalence of drug resistance (Figure 4A),
particularly in the pessimistic scenario, but only modest changes
occurred in infections prevented (Figure 4B). Specifically, the
prevalence of overall resistance fell from 2.5% to 1.5% in the
optimistic, 9.9% to 3.3% in the realistic and 42.3% to 4.5% in the
pessimistic scenario (Figure 2A and 4A).
Using the targeted-by-gender strategy (PrEP targeted to female
population), more infections were prevented in women compared
to men. These findings were generally robust (data not shown) to
single and multiple changes in the model’s key structural
assumptions including those related to balance in the supply and
demand of sexual partnerships in the population over time [29]
and infectivity of females on PrEP.
Trends in Resistance. Figure 5 shows the trends in the
overall prevalence drug resistance for 10 years after PrEP rollout.
After an initial rise, the overall resistance plateaued in the
pessimistic scenario, whereas it declined in optimistic and realistic
scenarios.
Discussion
Data from animal studies show that orally administered
antiretrovirals can prevent infection of macaques by simian
immunodeficiency virus [30]. The safety and efficacy of oral
antiretroviral PrEP in humans is being studied in several clinical
trials in the United States, Latin America, Africa and Asia [1]; the
results of the iPrEx trial are promising [2]. However, these studies
are not designed to address the population-level impact of PrEP
including potential HIV drug resistance consequences. Uncertain-
ty about HIV drug resistance from PrEP could prevent
deployment of PrEP even though it may be shown to prevent
HIV infection in clinical trials. Although PrEP implementation has
been modeled before by us [4] and others [31,32,33,34,35,36,37],
we report here for the first time the main drivers of drug resistance
from PrEP in a heterosexual HIV epidemic using a carefully
stratified and well-parameterized mathematical model of HIV
transmission. Inadvertent PrEP use in already infected individuals
is the key driver of increasing drug resistance in a heterosexual
population. The prevalence of drug resistance is influenced by
both the rate of uptake and duration of use of PrEP in this group.
Inadvertent PrEP use in already-infected individuals is not a
failure of PrEP per se, but it may occur as an unexpected
consequence of PrEP rollout programs and should be assiduously
avoided. The duration of PrEP use in susceptible individuals and
in individuals infected while on PrEP has less influence on drug
Figure 2. Outcomes after10 years of PrEP rollout in optimistic, realistic and pessimistic scenarios with four different strategies.
Panel A shows overall prevalence of HIV drug resistance and Panel B shows cumulative new HIV infections prevented.
doi:10.1371/journal.pone.0018165.g002
ARV PrEP and Drug Resistance
PLoS ONE | www.plosone.org 6 April 2011 | Volume 6 | Issue 4 | e18165resistance outcomes. As expected, the persistence times of
transmitted and acquired resistance were critical determinants of
the prevalence of transmitted and acquired resistance.
The current model represents a significant refinement of our
earlier version in terms of model structure, parameter assignment
and scenario design [4]. The current model also includes detailed
representations of both transmitted and acquired HIV drug
resistance, arising both in individuals who become infected while
on PrEP and in previously infected individuals exposed to PrEP.
These refinements provided improved precision of model output.
Assumptions regarding the effectiveness of PrEP (composite of
efficacy and adherence) in our optimistic and neutral scenarios are
in general agreement with the results of iPrEx [2], a clinical trial of
oral PrEP in men who have sex with men that showed a 44%
decrease in HIV incidence (95% confidence interval, 15 to 63).
Notwithstanding model improvements, sensitivity analyses of
infections prevented confirm our earlier findings of the impact of
PrEP on HIV prevention [4]. The parameters that most influence
the impact of PrEP are PrEP coverage, PrEP efficacy and
adherence, duration of PrEP use in susceptible individuals, and the
infectivity of individuals with acquired resistance. The estimated
decreases in HIV infections from PrEP are also in line with our
earlier work [4], but are more conservative due to deliberately
more pessimistic modeling assumptions, including lower estimates
of PrEP efficacy, adherence and coverage, higher rates of PrEP
discontinuation in susceptible individuals and significant PrEP
exposure in previously-infected individuals.
The results of our scenario analyses provide important insight
into potential emergence of HIV drug resistance after PrEP
implementation. The non-targeted optimistic and realistic scenar-
ios predicted low to moderate prevalence of drug resistance (2.5%
and 9.9% respectively) along with high to moderate decreases in
cumulative infections (30.3% and 6.6%, respectively). Uncertainty
analysis also predicted moderate levels of overall drug resistance.
With targeted optimistic and realistic scenarios, the prevalence of
resistance was modestly reduced with considerable erosion (up to
70%) of infections prevented. The prevalence of drug resistance
rose to over 40% in the pessimistic scenarios with minimal
reduction in HIV infections. Sensitivity analyses showed that the
key driver of this negative outcome was the high level of
inadvertent PrEP use in the already infected population. When
the pessimistic scenarios were re-simulated excluding PrEP use in
previously-infected individuals, the prevalence of resistance
decreased to 4.5%.
There are some important limitations of our current model
structure and the assumptions within it. The precise quantitative
detail of our predictions will be affected by variations in the sexual
activity patterns of different populations, for which data are very
limited, especially on sexual mixing patterns. However, we
employed a well-established template of sexual behavior [29],
with robust epidemiological and demographic parameterization,
broadly applicable to southern sub-Saharan Africa.
The actual impact of PrEP on drug resistance will depend on
the PrEP agent or agents used as well as the biological, behavioral
and viral characteristics of the HIV-infected population. Although
we do not model a specific PrEP agent, we used resistance-related
input estimates that would be expected for a single antiretroviral
drug used for PrEP such as tenofovir disoproxil fumarate [38,39].
We did not include combinations of antiretrovirals for PrEP in our
Figure 4. Outcomes after10 years of PrEP rollout assuming no inadvertent PrEP uptake in previously infected individuals for
optimistic, realistic and pessimistic scenarios, with four different strategies. Panel A shows overall prevalence of HIV drug resistance and
Panel B shows cumulative new HIV infections prevented.
doi:10.1371/journal.pone.0018165.g004
Figure 3. Overall prevalence of HIV drug resistance after 5, 10,
15 and 20 years of PrEP rollout predicted by uncertainty
analysis. For each time point, results of 10,000 simulations are shown
as a box-and-whisker plot; representing the median, upper and lower
quartiles, and maximum and minimum values.
doi:10.1371/journal.pone.0018165.g003
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studies of PrEP suggest superiority of tenofovir plus emtricitabine
over tenofovir alone [42,43], but it is unknown whether this will be
observed in human studies. Natural polymorphisms in HIV
subtypes may play an important role in drug resistance, including
the propensity of HIV subtype C virus that is predominant in Sub-
Saharan Africa for more frequent and rapid development of the
K65R tenofovir-resistance mutation noted by some investigators
[44], though not by others [45]. To address the substantial
uncertainty regarding PrEP-related resistance, we employed wide
ranges within plausible bounds for input parameters and
performed extensive sensitivity analyses. Our work underscores
the need for additional data on the persistence time of transmitted
and acquired resistance and the probability of transmission with
and without PrEP.
We excluded from our analyses the impact of antiretroviral
therapy for infected persons and various other influences on
transmission (e.g. STDs, circumcision and condom use). These
and other refinements will be addressed in future work.
Nevertheless, the important conclusion for our modeling is that
the spread of HIV drug resistance could be mitigated by limiting
inadvertent PrEP exposure in already infected individuals. To
accomplish this, PrEP implementation programs would need to be
tightly coupled with HIV testing of individuals who are candidates
for PrEP and monitoring of PrEP recipients for HIV infection and
drug resistance.
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